TRACON Pharmaceuticals (OTCPK:TCON) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

TCON 주식 개요

바이오 제약 회사인 TRACON 제약은 미국에서 새로운 암 표적 치료제의 개발 및 상용화에 주력하는 회사입니다.

TCON 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	1/6
과거 실적	2/6
재무 상태	3/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 99.4% 에서 거래

수익은 매년 49.96% 증가할 것으로 예상됩니다.

올해부터 흑자전환

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $3M )

최근 3개월간 주가 변동폭 심해

마이너스 주주 지분

+ 1 더 많은 위험

TRACON Pharmaceuticals, Inc. 경쟁사

MEI Pharma

NasdaqCM:MEIP

US$19.0m

Spero Therapeutics

NasdaqGS:SPRO

US$69.1m

Fennec Pharmaceuticals

NasdaqCM:FENC

US$171.3m

LadRx

OTCPK:LADX

US$1.2m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 TRACON Pharmaceuticals
과거 주가
현재 주가	US$0.85
52주 최고치	US$14.75
52주 최저치	US$0.66
베타	1.24
11개월 변경	-33.08%
3개월 변경 사항	-83.80%
1년 변경 사항	-85.60%
33년 변화	-99.31%
5년 변화	-99.27%
IPO 이후 변화	-99.95%

최근 뉴스 및 업데이트

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

주주 수익률

	TCON	US Biotechs	US 마켓
7D	-41.4%	-2.7%	1.1%
1Y	-85.6%	6.9%	22.5%

수익률 대 산업: TCON 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: TCON 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is TCON's price volatile compared to industry and market?
TCON volatility
TCON Average Weekly Movement	23.9%
Biotechs Industry Average Movement	10.2%
Market Average Movement	5.7%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.8%

안정적인 주가: TCON 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: TCON 의 주간 변동성( 25% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2004	17	Charles Theuer	www.traconpharma.com

바이오 제약 회사인 트레이콘 파마슈티컬스는 미국에서 새로운 암 표적 치료제의 개발과 상용화에 주력하고 있습니다. 임상 단계 제품으로는 난치성 연조직 육종 치료를 위한 PD-L1 단일 도메인 항체인 엔바폴리맙(KN035)과 다양한 암 적응증 치료를 위해 임상 1상 시험 중인 연구용 인간화 세포독성 T 림프구 관련 단백질 4 IgG1 단일 클론 항체 YH001이 있습니다. 또한 중피종 치료를 위한 임상 2상 및 고형암, 폐암, 교모세포종 치료를 위한 임상 1상 중인 저분자 항암제 TRC102와 고형암 치료를 위한 임상 1상 중인 CD73 항체 TJ004309도 임상 단계에 있습니다.

TRACON Pharmaceuticals, Inc. 기본 사항 요약

TRACON Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
TCON 기본 통계
시가총액	US$2.68m
수익(TTM)	US$1.75m
수익(TTM)	US$12.15m

1.3x

P/E 비율

0.2x

P/S 비율

TCON 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
TCON 손익 계산서(TTM)
수익	US$12.15m
수익 비용	US$9.19m
총 이익	US$2.96m
기타 비용	US$1.21m
수익	US$1.75m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	0.65
총 마진	24.36%
순이익 마진	14.39%
부채/자본 비율	0%

TCON 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

TCON 주식 개요

보상

위험 분석

TRACON Pharmaceuticals, Inc. 경쟁사

NasdaqCM:MEIP

US$19.0m

NasdaqGS:SPRO

US$69.1m

NasdaqCM:FENC

US$171.3m

OTCPK:LADX

US$1.2m

가격 내역 및 성능

최근 뉴스 및 업데이트

TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index

Investor sentiment improves as stock rises 16%

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

Price target decreased by 19% to US$30.50

Recent updates

TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index

Investor sentiment improves as stock rises 16%

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

The Nasdaq Hearings Panel Determines to Delist TRACON Pharmaceuticals' Common Stock from Nasdaq Due to Non-Compliance with Continued Listing Requirements by June 3, 2024

Price target decreased by 19% to US$30.50

Forecast to breakeven in 2026

TRACON Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.